Searchable abstracts of presentations at key conferences in endocrinology

ea0014p277 | (1) | ECE2007

Adrenal incidentalomas: aberrant expression of hormone receptors (preliminary results)

Mena Elena , Sahun Manel , Alià Pedro , Navarro M Ángel , Soler Joan , Villabona Carles

Background: In some patients with adrenal tumors cortisol regulation may be under the control of abnormal or ectopic hormone receptors. The objective of this study is investigate the presence of these aberrant receptors in subjects with adrenal incidentaloma and biochemical criteria of subclinical hypercortisolism.Patients and methods: We studied seventeen patients with adrenal incidentalomas, ten patients with a unilateral tumor (age 48–70, M/F: 4/...

ea0011p751 | Steroids | ECE2006

Human endothelial cells (HUVECs) potentiate aldosterone secretion from human adrenocortical cells through a PKA independent pathway

Ansurudeen I , Krug AW , Kopprasch S , Ehrhart-Bornstein M , Bornstein SR

The mineralocorticoid hormone aldosterone is secreted by the adrenal cortex. It plays a major role in maintaining water and electrolyte balance and hence blood pressure homeostasis by the kidneys. The aldosterone synthesizing zona glomerulosa of the adrenal cortex is a highly vascularized region. This allows a complex and articulated interaction between the steroidogenic cells and the vascular endothelial cells regulating the hormonal output.In this stud...

ea0029p1761 | Thyroid cancer | ICEECE2012

Differential proteomics in human normal or papillary thyroid carcinoma cell cultures

Rodrigues J , Garcia-Rendueles M , Garcia-Rendueles A , Perez S , Barreiro F , Cameselle-Teijeiro J , Alvarez C , Bravo S

Up to now there are few studies about differential proteomics in thyroid. Our group has developed a method for standard human primary thyroid culture maintaining the phenotype through passages. Thus, we believe of great interest the search for biomarkers in these cultures by 2D-PAGE coupled to MALDI-TOF/TOF-MS.Aims: i) To standardize the conditions for sample extraction and controls. ii) To compare and identify the differential proteomic pattern between ...

ea0029p537 | Diabetes | ICEECE2012

Relationship between serum levels of 1-84 parathormone (PTH1-84) and obesity, HOMA insulin-sensitivity or beta-cells function (HOMA-B) in type 2 diabetic patients

Belovici M. , Buysschaert M.

Introduction: PTHrP (Parathyroid hormone-related protein) is known to enhance beta cell function and proliferation. PTH levels predict myocardial and coronary heart disease in non-diabetic patients with normal calcium levels and no kidney failure. We aimed at determining in type 2 diabetes patients without kydney failure the relationship between serum levels of 1-84 parathormone (PTH1-84), obesity, HOMA insulin-sensitivity or beta-cells function (HOMA-B), but also between PTH1...

ea0029p883 | Endocrine tumours and neoplasia | ICEECE2012

Clinically palpable parathyroid adenoma

Kaushal M. , Nagar M.

A palpable parathyroid mass, in a patient with primary hyperparathyroidism, is presumed to be parathyroid carcinoma until proven otherwise, with other less common causes including parathyroid cysts and adenomas.In developing world primary hyperparathyroidism presented in different way not only in the disease age group as well as in clinical symptoms and signs. More cases of symptomatic PHPT are presented in younger age group and some time large adenomas ...

ea0029p1757 | Thyroid cancer | ICEECE2012

Optimal prophylactic and definitive therapy for bicalutamide induced gynaecomastia: results of meta-analysis

Tunio M , Asiri M

Objective: Bicalutamide is approved as an adjuvant to primary treatments (radical prostatectomy or radiotherapy) or as monotherapy in men with locally advanced, nonmetastatic prostate cancer (PCa); however, this treatment induces gynaecomastia in most of patients, which results in treatment withdrawal. Optimal therapy for these breast events is not known so far. We conducted a meta-analysis to assess the efficacy of different treatment options for bicalutamide induced gynaecom...

ea0029p1774 | Thyroid cancer | ICEECE2012

Role of intensity modulated radiation therapy in patients with non-anaplastic thyroid carcinoma: king fahad medical city experience

Tunio M. , Asiri M.

Background: To evaluate outcomes and toxicities in patients with non-anaplastic thyroid cancer treated with intensity modulated radiation therapy (IMRT).Materials and methods: This was a single institution retrospective review of 18 patients with non-anaplastic thyroid cancer treated with IMRT at King Fahad Medical City between April 2005 and December 2010. The median age was 69 years. Among the 18 patients, fifteen had papillary carcinoma, two had T3 an...

ea0016me13 | (1) | ECE2008

Endocrine management of gonadal tissue conservation

Dolmans M M

Advances in the diagnosis and treatment of childhood, adolescent and adult cancer have greatly increased the life expectancy of young women with cancer, but have resulted in a growing population of adolescent and adult long-term survivors of childhood malignancies, who may experience premature ovarian failure (POF) and infertility as a result of aggressive chemotherapy and radiotherapy treatments (indicated for both cancer and bone marrow transplantation (BMT)).<p class="a...

ea0009p211 | Clinical | BES2005

Evolving tumour behaviour in a patient with combined Conn's and Cushing's syndrome

Forbes M , Daly M

In 1993 a 33-year old female was diagnosed biochemically with both Conn's and Cushing's syndrome. A large right-sided adrenal mass was found on CT scan of the abdomen and a right-sided adrenalectomy was performed. Histology reported a benign, 7 centimetre adrenocortical tumour, secreting both cortisol and aldosterone. Annual assessments of urinary cortisol and plasma aldosterone/renin ratios remained normal until September 2002, when she noticed a weight gain of 6 kilograms an...

ea0070aep224 | Bone and Calcium | ECE2020

Efficacy of teriparatid therapy in resistant hypocalcemia depending postoperative hypoparathyroidism

Durmuș Buğra , Karaahmetli Gülsüm , Keskin Müge , Tural Balsak Belma , Bașer Hüsniye , Berker Dilek

Objective: While postoperative hypoparathyroidism can usually be controlled with elemental calcium (Ca) and calcitriol therapy, rarely this treatment may be inadequate and teriparatid therapy may be used as an alternative. In the literature, it is reported that teriparatid therapy is effective and reliable in the treatment of patients with postoperative hypoparathyroidism, as well as improving quality of life and reducing the frequency of hospitalization. In this report, we pr...